Oncologists tap the microbiome in bid to improve immunotherapy outcomes
Nature Reviews Drug Discovery 17, 153 (2018).
doi:10.1038/nrd.2018.19
Author: Asher Mullard
A pioneering Merck & Co.-funded study is set to explore the ability of the microbiome to boost immuno-oncology therapy outcomes, and other companies are quickly gearing up to enter this clinical space.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research